Advanced

Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials : A Harmonising Outcome Measures for Eczema (HOME) statement

Spuls, P. I.; Gerbens, L. A A; Simpson, E.; Apfelbacher, C. J.; Chalmers, J. R.; Thomas, K. S.; Prinsen, C. A C; von Kobyletzki, L. B. LU ; Singh, J. A. and Williams, H C, et al. (2017) In British Journal of Dermatology 176(4). p.979-984
Abstract

Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has defined four core outcome domains for a core outcome set (COS) to be measured in all atopic eczema (AE) trials to ensure cross-trial comparison: clinical signs, symptoms, quality of life and long-term control. Objectives: The aim of this paper is to report on the consensus process that was used to select the core instrument to consistently assess symptoms in all future AE trials. Methods: Following the HOME roadmap, two systematic reviews were performed which identified three instruments that had sufficient evidence of validity, reliability and feasibility to be considered for the final COS. Results: At the fourth international HOME meeting, there was broad... (More)

Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has defined four core outcome domains for a core outcome set (COS) to be measured in all atopic eczema (AE) trials to ensure cross-trial comparison: clinical signs, symptoms, quality of life and long-term control. Objectives: The aim of this paper is to report on the consensus process that was used to select the core instrument to consistently assess symptoms in all future AE trials. Methods: Following the HOME roadmap, two systematic reviews were performed which identified three instruments that had sufficient evidence of validity, reliability and feasibility to be considered for the final COS. Results: At the fourth international HOME meeting, there was broad consensus among all stakeholders that the Patient-Oriented Eczema Measure (POEM) should be used as the core instrument (87·5% agreed, 9·4% unsure, 3·1% disagreed). Conclusions: All relevant stakeholders are encouraged to use POEM as the chosen instrument to measure the core domain of symptoms in all future AE clinical trials. Other instruments of interest can be used in addition to POEM.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Dermatology
volume
176
issue
4
pages
979 - 984
publisher
Wiley-Blackwell
external identifiers
  • scopus:85014113737
  • wos:000399363100043
ISSN
0007-0963
DOI
10.1111/bjd.15179
language
English
LU publication?
yes
id
a908899f-6aad-4af2-8170-b812e0eb0aad
date added to LUP
2017-03-15 14:40:40
date last changed
2018-05-20 04:32:26
@article{a908899f-6aad-4af2-8170-b812e0eb0aad,
  abstract     = {<p>Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has defined four core outcome domains for a core outcome set (COS) to be measured in all atopic eczema (AE) trials to ensure cross-trial comparison: clinical signs, symptoms, quality of life and long-term control. Objectives: The aim of this paper is to report on the consensus process that was used to select the core instrument to consistently assess symptoms in all future AE trials. Methods: Following the HOME roadmap, two systematic reviews were performed which identified three instruments that had sufficient evidence of validity, reliability and feasibility to be considered for the final COS. Results: At the fourth international HOME meeting, there was broad consensus among all stakeholders that the Patient-Oriented Eczema Measure (POEM) should be used as the core instrument (87·5% agreed, 9·4% unsure, 3·1% disagreed). Conclusions: All relevant stakeholders are encouraged to use POEM as the chosen instrument to measure the core domain of symptoms in all future AE clinical trials. Other instruments of interest can be used in addition to POEM.</p>},
  author       = {Spuls, P. I. and Gerbens, L. A A and Simpson, E. and Apfelbacher, C. J. and Chalmers, J. R. and Thomas, K. S. and Prinsen, C. A C and von Kobyletzki, L. B. and Singh, J. A. and Williams, H C and Schmitt, J.},
  issn         = {0007-0963},
  language     = {eng},
  number       = {4},
  pages        = {979--984},
  publisher    = {Wiley-Blackwell},
  series       = {British Journal of Dermatology},
  title        = {Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials : A Harmonising Outcome Measures for Eczema (HOME) statement},
  url          = {http://dx.doi.org/10.1111/bjd.15179},
  volume       = {176},
  year         = {2017},
}